|
|
Zhaosheng Lin
Head of Biomarkers
Pfizer
 Nadine Cohen Head of Pharmacogenomics
Johnson & Johnson
 Mitchell B. Friedman Director of Toxicology
Takeda Global R&D
 Malcolm Mitchell Medical Director, Clinical Pharmacology
Eli Lilly
 Dr Russell Weiner Group Director
Bristol-Myers Squibb
|
Conference:
Pre-conference workshop
19 Oct 9am - 5pm
Day 1
20 Oct 8.30am - 5:30pm
Day 2
21 Oct 8.30am - 5:30pm
Post-conference workshop
22 Oct 9am - 5pm
Venue: Boston, MA, United States
› Email a friend
› Add this to my calendar
|
|
|
Dr Jonathan Deutsch,
Safety Science Leader, Director Pharma Development Safety, Licensing and Early Development Hoffman-La Roche Inc Jonathan Deutsch, M.D. is a graduate of the University of Rochester and The Sackler School of Medicine. Dr. Deutsch completed his internship at Overlook Hospital in Summit, NJ, USA in the Department of Internal Medicine, and he completed his training in Anesthesiology and Pain Management at the Mount Sinai School of Medicine in New York City. Dr. Deutsch received Board Certification in Anesthesiology and additional Board Certification in Pain Management. Early in his career, Dr. Deutsch joined the faculty of the Anesthesiology Department of the Mount Sinai School of Medicine in NY. He has enjoyed working in academic medicine, private practice and in a variety of pharmaceutical industry roles.
Since moving to the pharmaceutical industry 13 years ago, Dr. Deutsch has held a range of positions of increasing responsibility while working at Organon, Bristol-Myers Squibb, Baxter and Roche. Dr. Deutsch has worked in Medical Affairs and Clinical Development focusing on Risk Management and Clinical Trials of marketed and pipeline products ranging from phase 1 to 4 trials. His Pharmacovigilance experience includes heading up Organon’s US Drug Safety Department.
Since April 2007, Dr. Deutsch has been Safety Science Leader in the Roche Oncology Licensing and Early Development Drug Safety group. His work at Roche includes a mechanistic approach to safety and signal detection
Appearing: Day One, Wednesday 20 October 2010 3pm Drug Safety Strategy in Early Development
- Examples of product recalls, understanding why drug withdrawals occur and their impact
- Demonstrate that the understanding of the mechanism of action of a new drug helps with risk minimization
- Discuss proactive measures to mitigate risk
Dr Jonathan Deutsch, Safety Science Leader, Director Pharma Development Safety, Licensing and Early Development,
Hoffman-La Roche Inc |
|
|
|
|
|
Reserve an exhibition stand at the Exploratory Clinical Development World Americas exhibition - book early to ensure optimum stand placement!
| |
Reserve a stand
For details contact
Claire Conway on +44 (0) 207 608 7058 |
|
|
|
|
|
|
|
|
|
